Engineered cells overexpressing FoxP3 and harboring an anti-CD19 second-generation CAR prove effective in controlling B cell activation in vitro and in restoring the human immune system composition in lymphoid organs in an ad hoc humanized mouse model of SLE. Here, CD19 is linked to systemic lupus erythematosus.